News | November 12, 2014

QT Vascular Acquires Java

The first product in the Java product line is an aortic valvuloplasty balloon for use as a pre-dilatation device prior to a TAVR

TriReme, PTA Chocolate Balloon, valvuloplasty, heart valve repair

Nov. 12, 2014 — Catalist-listed QT Vascular Ltd. has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.

The first product in the Java product line is an aortic valvuloplasty balloon for use as a pre-dilatation device prior to a TAVR (Transcatheter Valve Replacement) procedure or a stand-alone treatment in select patients where TAVR is not appropriate. It is designed to be a highly deliverable, puncture resistant device that has proprietary tines which aid in stability and reduce the need for peri-procedural cardiac pacing. Minimally invasive angioplasty is the core expertise of QT Vascular today, and the Java aortic valvuloplasty balloon is a natural extension of the Group's technology offering to a new therapeutic indication.

The acquisition of this novel technology platform is in line with QT Vascular's efforts to grow its new product pipeline in recent months. The acquisition of this technology is not expected to have a material financial impact on the Group's earnings per share and net tangible assets per share for the current financial year ending 31 December 2014.On15 September 2014, QT Vascular announced that it has enrolled the first European patient in the ENDURE Trial inGermany. Patients' enrollment in Germany and New Zealand is progressing rapidly and is consistent with the group's expectations. The Group previously announced that it has applied for CE marking approval with respect to the ChocolateTouch, its advanced drug coated peripheral balloon.

QT Vascular also disclosed that its wholly owned US subsidiary, TriReme Medical LLC, received notification from the United States Food and Drug Administration (FDA) of 510(K) clearance to market the Chocolate Percutaneous Transluminal Coronary Angioplasty Balloon Catheter ("Chocolate PTCA") in the United States.

For more information: www.qtvascular.com

Related Content

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init